No information
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Acute asthma attack |
|---|
|
| Bronchial dilation (short-acting) in intermittent asthma complaints |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
When administering a beta-2-sympathomimetic to children younger than 1 year, possible increases of dyspnoea and/or (transient) hypoxaemia due to a counterproductive effect of the relaxation of the bronchus musculature should be taken into account.
Short-acting sympathomimetics are used in episodes of bronchoconstriction. As a monotherapy, they have no effect or even an unfavourable effect on the bronchial hyperreactivity.
When insufficiently monitoring asthma according to the GINA guideline step 2 must be switched to according to SKL asthma consensus (adding an inhalation corticosteroids)
The choice of formulation is dependent on the age and preference of the patient. It is preferable to prescribe a dosing aerosol in combination with a holding chamber due to better lung deposition: Babyhaler (1-4 years), Volumatic (> 4 years), AeroChamber with baby mask 0-1 years; with child mask 1-4 years; with mouthpiece > 4 years). A holding chamber should be used in combination with a mask in children aged under 4 years. In children of > 7 years there is the option for an autohaler or dry powder inhaler (Diskus, Novolizer, Cyclohaler, Easyhaler, Clickhaler). The use of dry powder inhalers (DPI) by children: most clinical studies were done with the Turbuhaler and the Diskus). There are little to no known studies about the use of other DPIs by children aged under 12 years.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Selective beta-2-adrenoreceptor agonists | ||
|---|---|---|
| R03AC03 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.